Search | IOVS | ARVO Journals

Access Provided By:
MIT Libraries

Forgot password?

Create an Account

View

Showing 1 – 9 of 9

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2024

Pharmacodynamic efficacy of second-generation intravitreal axitinib implant (Axpaxli™) in a VEGF challenge rabbit model

Charles Blizzard; Chintan Patel; MADHOOSUDAN PATIL; Erica Kahn; Joe Iacona; Daniel Domingues; Alyssa Whalen; Olivia Sherman; Mark Ransbottom; Dinesh Haswani; Rabia Gurses Ozden; Peter Jarrett

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):6520.

ARVO Annual Meeting Abstract June 2024

Optimized pharmacokinetic profile of intravitreal axitinib intravitreal implant (Axpaxli™): a comparison of first- and second-generation implants

MADHOOSUDAN PATIL; Chintan Patel; Erica Kahn; Joe Iacona; Daniel Domingues; Alyssa Whalen; Charles Blizzard; Olivia Sherman; Mark Ransbottom; Dinesh Haswani; Rabia Gurses Ozden; Peter Jarrett

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):1937.

ARVO Annual Meeting Abstract June 2024

Long-term safety of repeated intravitreal axitinib implant (Axpaxli™) administrations in non-human primates

Chintan Patel; MADHOOSUDAN PATIL; Erica Kahn; Joe Iacona; Daniel Domingues; Alyssa Whalen; Charles Blizzard; Olivia Sherman; Mark Ransbottom; Dinesh Haswani; Rabia Gurses Ozden; Peter Jarrett

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):1936.

ARVO Annual Meeting Abstract June 2022

A 6-Month GLP Toxicology Study of a Novel Hydrogel-based, Axitinib Intravitreal Implant (OTX-TKI) in Non-Human Primates

Chintan Patel; Erica Kahn; Megan Priem; Joe Iacona; Andrew Vanslette; Erik Wong; Charles D Blizzard; Peter K Jarrett; Michael Goldstein; Rabia Gurses-Ozden

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):298 – F0101.

ARVO Annual Meeting Abstract June 2022

A Safety and Pharmacokinetic Study of a Novel Hydrogel-based Axitinib Intravitreal Implant (OTX-TKI) in Non-Human Primates

Erica Kahn; Chintan Patel; Megan Priem; Joe Iacona; Andrew Vanslette; Erik Wong; Charles D Blizzard; Peter K Jarrett; Michael Goldstein; Rabia Gurses-Ozden

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):297 – F0100.

ARVO Annual Meeting Abstract July 2019

Pharmacodynamic Effect and Corneal Wound Healing of OTX-BPI, a Sustained Release Bupivacaine Intracanalicular Hydrogel Insert in Beagle Dogs

Rami F Elhayek; Jacob Dexter; Nelson Bello; Erica Kahn; Stephanie Manning; Charles D Blizzard; Arthur Driscoll; Jamie L Metzinger; Michael H Goldstein; Peter K Jarrett

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):2099.

ARVO Annual Meeting Abstract July 2019

Efficacy & Tolerability of OTX-TKI, a Sustained Hydrogel Delivery System for a Tyrosine Kinase Inhibitor, in a VEGF Induced Retinal Leakage Model: 1 Year Results

Peter K Jarrett; Rami F Elhayek; Erica Kahn; Stephen Takach; Jamie L Metzinger; Michael H Goldstein

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):372.

ARVO Annual Meeting Abstract July 2018

Effectiveness of Sustained Release TKI Hydrogel Combined with Bevacizumab in a VEGF Induced Retinal Leakage Model Through 12 Months

Rami F Elhayek; Tim Jarrett; Zachary Lattrell; Erica Kahn; Stephen Takach; Jamie Lynne Metzinger; Michael H Goldstein; Peter K Jarrett; Amar Sawhney

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):245.

ARVO Annual Meeting Abstract July 2018

Efficacy & Tolerability of OTX-TKI, a Sustained Hydrogel Delivery System for a Tyrosine Kinase Inhibitor, in a VEGF Induced Retinal Leakage Model Through 12 Months

Peter K Jarrett; Rami F Elhayek; Tim Jarrett; Zachary Lattrell; Erica Kahn; Stephen Takach; Jamie Lynne Metzinger; Michael H Goldstein; Amar Sawhney

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):3465.

Advertisement